Key facts
- Nouri’s last known valuation is $4.0M (May 2019).
- It has raised $160K; the latest was Later Stage VC in Jun 2025.
- Notable investors include HEPCO Capital Management, EY Ventures Group, Jumpstart Foundry, Target Accelerators.
- 1 investment vehicle was formed to buy Nouri shares in the last 12 months, reporting $75K sold to 4 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nouri
- ·The full record, as it builds
Funding rounds
No funding rounds for Nouri are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Nouri shares, reporting $75K sold to 4 investors. Most recent filing Feb 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Nouri
Producer of probiotic supplements intended to improve gut health and also offer benefits to the body in specific ways. The company's supplements have no additives, contain plant-based omega oil, offer an effective amount of colony-forming unit count, and do not need refrigeration, enabling consumers to strengthen their digestive and immune systems.
- Sector
- Healthcare
- HQ
- Conyers, GA, United States
- Founded
- 2018
- Employees
- 6
- Website
- dailynouri.com/
- Ownership
- Privately Held (backing)
Nouri doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nouri shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nouri in its N-PORT filings yet. We sweep new filings monthly.